OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Giaccone on Investigational Agents in Thymic Cancers

October 21st 2022

Giuseppe Giaccone, MD, PhD, discusses recent data with investigational therapies for patients with thymic cancer.

Dr. Giaccone on the Challenge of Diagnosing Thymic Cancers

October 21st 2022

Giuseppe Giaconne, MD, PhD, discusses why thymic cancers can be difficult to classify histologically, so the actual incidence is unclear.

Drs Giaccone and He on Raising Awareness in Thymic Cancers

October 21st 2022

Giuseppe Giaconne, MD, PhD, and Yongfeng He, PhD, discuss how cancers of the thymus, a small organ located in the mediastinum above the heart, are uncommon and understudied.

Dr. Llanos on the Role of Social and Biological Determinants on Cancer Risk

October 20th 2022

Adana A.M. Llanos, PhD, MPH, discusses the role of social and biological determinants on cancer risk.

Dr. Vunjak-Novakovic on the Clinical Need for Personalizing Cancer Care

October 20th 2022

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

Dr. Baccarelli on the Effect of Environmental Factors on Cancer Diagnoses

October 20th 2022

Andrea Baccarelli, MD, PhD, discusses the effect of environmental factors on cancer diagnoses.

Dr. Camidge on Toxicities of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

October 20th 2022

Ross Camidge, MD, PhD, discusses toxicities observed with sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer.

Dr. Gross on the Investigation of Cemiplimab in Cutaneous Squamous Cell Carcinoma

October 20th 2022

Neil D. Gross, MD, FACS, discusses the investigation of cemiplimab in cutaneous squamous cell carcinoma.

Dr. Aggarwal on ADT Intensification in Biochemically Relapsed Prostate Cancer

October 20th 2022

Rahul Aggarwal, MD, discusses the rationale for investigating androgen deprivation therapy intensification in biochemically relapsed prostate cancer.

Dr. Paul on the Future of CAR T-Cell Therapy in Multiple Myeloma Treatment

October 18th 2022

Barry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.

Dr. Jain on the Benefit of CDK7 Inhibitors in HR+ Breast Cancers

October 18th 2022

Amit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.

Dr. Awan on the Evolution of Treating Frontline CLL

October 18th 2022

Farrukh Awan, MD, discusses the evolution of treating frontline chronic lymphocytic leukemia.

Dr. Gupta on the Investigation of Cabozantinib Plus Avelumab in Metastatic Urothelial Cancer

October 18th 2022

Shilpa Gupta, MD, discusses the addition of cabozantinib to avelumab in locally advanced or metastatic urothelial cancer.

Dr. Yorio on the Safety of Targeted Therapies in BRAF-Mutated Melanoma

October 18th 2022

Jeff Yorio, MD, discusses adverse effects associated with targeted agents and combinations in BRAF-mutated melanoma.

Dr. Mascarenhas on the Potential Clinical Significance of Pacritinib in Myelofibrosis

October 18th 2022

John O. Mascarenhas, MD, discusses the potential clinical significance of pacritinib in patients with myelofibrosis.

Dr. Shallis on the Investigation of Uproleselan in AML

October 18th 2022

Rory Shallis, MD, discusses the investigation of uproleselan in acute myeloid leukemia.

Dr. Abou-Alfa on Analyzing Disease Factors to Inform Clinical Decisions in HCC

October 18th 2022

Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.

Dr. Goff on Leveraging Clinical Trial Information to Inform Treatment Decisions in HCC

October 18th 2022

Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.

Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer

October 18th 2022

Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Dr. Iams on Small Cell Lung Cancer Subtyping in Clinical Practice

October 17th 2022

Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.